Abstract: The present application relates to a novel benzoazepine compound, comprising a pharmaceutically acceptable salt thereof. The present application also provides a pharmaceutical composition comprising the compound and a pharmaceutically acceptable salt thereof. The present application relates to use of the compound and the composition in the prevention or treatment of diseases related to arginine vasopressin V1a receptor, arginine vasopressin V1b receptor, arginine vasopressin V2 receptor, sympathetic nervous system or renin-angiotensin-aldosterone system. The present application also provides a method for preventing and/or treating arginine vasopressin-related diseases.

Abstract: The invention relates to the technical field of computer-aided design of integrated circuits, and provides a two-step X-architecture Steiner minimum tree construction method for very large scale integration (VLSI). Based on the advantages of an X-architecture model and a particle swarm optimization technique, the method is implemented through two steps: (1) the stage of social learning discrete particle swarm search, which comprises: using an edge-vertex encoding strategy capable of maintaining optimal topological information of particles, designing a fitness function taking wirelength into consideration; and using a chaotic decreasing mutation strategy and a new social learning strategy to design a new discrete particle swarm update formula; and (2) a stage of wirelength optimization, which comprises: designing a local topological optimization strategy to minimize the wirelength of an X-architecture Steiner tree.

Abstract: The present disclosure provides fully human antibodies that specifically bind the spike (S) protein of the SARS-CoV-2 coronavirus with high affinity, or antigen-binding proteins derived from such antibodies, and uses thereof. Included are anti-spike protein antibodies, antibody fragments, and single-chain antibodies, that are coronavirus neutralizing antibodies, as well as pharmaceutical compositions that include such antibodies and antibody fragments. Methods for using the anti-spike protein antibodies include methods of treating or preventing infection with a coronavirus, such as the SARS-CoV-2 coronavirus, by administering an antibody or antibody fragment as disclosed herein, including by intranasal delivery. Methods and compositions for treating or preventing coronavirus infection by administering a composition that includes a nucleic acid construct that encodes a neutralizing antibody are also provided.

Abstract: A DRL-based control logic design method for continuous microfluidic biochips is provided. Firstly, an integer linear programming model is for effectively solving multi-channel switching calculation to minimize the number of time slices required by the control logic. Secondly, a control logic synthesis method based on deep reinforcement learning, which uses a double deep Q network and two Boolean logic simplification techniques to find a more effective pattern allocation scheme for the control logic.

Abstract: The invention relates to the technical field of computer-aided design of integrated circuits, and provides a two-step X-architecture Steiner minimum tree construction method for very large scale integration (VLSI). Based on the advantages of an X-architecture model and a particle swarm optimization technique, the method is implemented through two steps: (1) the stage of social learning discrete particle swarm search, which comprises: using an edge-vertex encoding strategy capable of maintaining optimal topological information of particles, designing a fitness function taking wirelength into consideration; and using a chaotic decreasing mutation strategy and a new social learning strategy to design a new discrete particle swarm update formula; and (2) a stage of wirelength optimization, which comprises: designing a local topological optimization strategy to minimize the wirelength of an X-architecture Steiner tree.

Abstract: The present disclosure provides dimeric antigen receptors (DAR) constructs that bind a CD20 target antigen, where the DAR construct comprises a heavy chain binding region on one polypeptide chain and a light chain binding region on a separate polypeptide chain. The two polypeptide chains that make up the dimeric antigen receptors can dimerize to form an antigen binding domain. The dimeric antigen receptors have antibody-like properties as they bind specifically to a target antigen. The dimeric antigen receptors can be used for directed cell therapy.

Abstract: A multi-stage FPGA routing method for optimizing time division multiplexing comprises the following steps: S1: collecting an FPGA set, an FPGA connection pair set, a net set and a net group set; S2: acquiring a routing topology of each net according to the FPGA set, the FPGA connection pair set, the net set and the net group set under the condition where TRs are not assigned; S3: assigning a corresponding TR to each edge of each net according to different delay of each net group; and S4: performing TR reduction and edge validation cyclically, iteratively optimizing net groups with TR being greater than a preset value until iteration end conditions are met, so as to obtain an optimal routing result. The multi-stage FPGA routing method may optimize the delay of inter-chip signals of a multi-FPGA prototype system and guarantee the routability of the multi-FPGA prototype system.

Abstract: The present disclosure provides dimeric antigen receptors (DAR) constructs that bind a BCMA target antigen, where the DAR construct comprises a heavy chain binding region on one polypeptide chain and a light chain binding region on a separate polypeptide chain. The two polypeptide chains that make up the dimeric antigen receptors can dimerize to form an antigen binding domain. The dimeric antigen receptors have antibody-like properties as they bind specifically to a target antigen. The dimeric antigen receptors can be used for directed cell therapy.

Abstract: There is disclosed an improved, safer and commercially efficient process for developing genetically engineered cells. More specifically, there is disclosed a process comprises introducing a donor DNA construct, a guide RNA, and an RNA-guided nuclease with the host cells to he transfected; and introducing the three components into the host cell. There is further disclosed a donor DNA construct designed for inserting a CAR (chimeric antigen receptor) into a defined genomic site of a host cell. Further, the present disclosure provides a host cell transfected with a CAR that lacks viral vectors that can present a safety concern. The disclosure provides for more efficient and more cost-effective process for engineering T cells to express CAR constructs.

Abstract: There is disclosed an improved, safer and commercially efficient process for developing genetically engineered cells. More specifically, there is disclosed a process comprises introducing a donor DNA construct, a guide RNA, and an RNA-guided nuclease with the host cells to be transfected; and introducing the three components into the host cell. There is further disclosed a donor DNA construct designed for inserting a CAR (chimeric antigen receptor) into a defined genomic site of a host cell. Further, the present disclosure provides a host cell transfected with a CAR that lacks viral vectors that can present a safety concern. The disclosure provides for more efficient and more cost-effective process for engineering T cells to express CAR constructs.

Abstract: The present disclosure relates to a realtime urban traffic status monitoring method based on privacy-preserving compressive sensing, including the following steps: step S1: dividing vehicle data under privacy preserving into two parts, and sending the two parts to two different road side units (RSU) for preprocessing; step S2: outsourcing, by the two different RSUs, preprocessed vehicle data to two cloud platforms (CP) respectively, and designing a data encryption execution protocol based on a finally expected operation result and interactive operation between the two CPs, to encrypt the data; and step S3: receiving, by a navigation service provider (NSP), encrypted data from the CPs, decrypting the received encrypted data, and estimating an urban traffic status by using a compressive sensing technology.

Abstract: The present disclosure relates to a realtime urban traffic status monitoring method based on privacy-preserving compressive sensing, including the following steps: step S1: dividing vehicle data under privacy preserving into two parts, and sending the two parts to two different road side units (RSU) for preprocessing; step S2: outsourcing, by the two different RSUs, preprocessed vehicle data to two cloud platforms (CP) respectively, and designing a data encryption execution protocol based on a finally expected operation result and interactive operation between the two CPs, to encrypt the data; and step S3: receiving, by a navigation service provider (NSP), encrypted data from the CPs, decrypting the received encrypted data, and estimating an urban traffic status by using a compressive sensing technology.

Abstract: Provided are a chimeric antigen receptor and an application thereof; said chimeric antigen receptor contains a domain which identifies any one of, or a combination of at least two of, the malarial protein VAR2CSA, a protein tag on malarial protein VAR2CSA, or a compound capable of labeling the malarial protein VAR2CSA. The chimeric antigen receptor can identify the VAR2CSA protein or the recombinant protein (rVAR2) of any one of, or at least two of, the domains of the VAR2CSA protein which can bind to placental-like chondroitin sulfate A (pl-CSA). The VAR2CSA protein or rVAS2 protein is capable of targeting several different types of tumor cells by means of binding to the pl-CSA on the surface of the tumor cell.

Abstract: The present disclosure provides dimeric antigen receptors (DAR) constructs comprising a heavy chain binding region on one polypeptide chain and a light chain binding region on a separate polypeptide chain. The two polypeptide chains that make up the dimeric antigen receptors can dimerize to form an antigen binding domain. The dimeric antigen receptors have antibody-like properties as they bind specifically to a target antigen. The dimeric antigen receptors can be used for directed cell therapy.

Abstract: There is disclosed an improved, safer and commercially efficient process for developing genetically engineered cells. More specifically, there is disclosed a process comprises introducing a donor DNA construct, a guide RNA, and an RNA-guided nuclease with the host cells to be transfected; and introducing the three components into the host cell. There is further disclosed a donor DNA construct designed for inserting a CAR (chimeric antigen receptor) into a defined genomic site of a host cell. Further, the present disclosure provides a host cell transfected with a CAR that lacks viral vectors that can present a safety concern. The disclosure provides for more efficient and more cost-effective process for engineering T cells to express CAR constructs.

Abstract: The present invention provides an anti-placenta chondroitin sulfate (pl-CS) chimeric antigen receptor and application thereof. The chimeric antigen receptor mainly comprises anti-pl-CS antigen recognition region, a hinge region, a transmembrane region and intracellular region, wherein the anti-pl-CS antigen recognition region is any one of a plasmodium protein VAR2CSA, a part of peptide segment of plasmodium protein VAR2CSA or a pl-CS antibody; and the part of peptide segment of the plasmodium protein VAR2CSA is a peptide segment with the number of amino acid greater than 500 in the plasmodium protein VAR2CSA.